

Alan Bonder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/871260/publications.pdf>

Version: 2024-02-01

55
papers

1,061
citations

394421

19
h-index

454955

30
g-index

56
all docs

56
docs citations

56
times ranked

1316
citing authors

#	ARTICLE	IF	CITATIONS
1	Waitlist and posttransplantation outcomes of lean individuals with nonalcoholic fatty liver disease. <i>Liver Transplantation</i> , 2023, 29, 145-156.	2.4	3
2	Introduction of a standardized protocol for cardiac risk assessment in candidates for liver transplant – A retrospective cohort analysis. <i>Annals of Hepatology</i> , 2022, 27, 100582.	1.5	6
3	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	3.7	21
4	Cholestatic Liver Disease and Pregnancy: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1068.	2.4	2
5	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 1545-1553.	3.7	33
6	Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 936-942.	2.8	37
7	Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis. <i>Journal of Hepatology</i> , 2021, 74, 48-57.	3.7	33
8	Management of Autoimmune Liver Diseases after Liver Transplantation. <i>Transplantology</i> , 2021, 2, 162-182.	0.6	6
9	A randomized placebo-controlled trial of elafibanor in patients with primary biliary cholangitis and incomplete response to UDCA. <i>Journal of Hepatology</i> , 2021, 74, 1344-1354.	3.7	77
10	Waitlist mortality and transplant free survival in Hispanic patients listed for liver transplant using the UNOS database. <i>Annals of Hepatology</i> , 2021, 23, 100304.	1.5	9
11	Waitlist Mortality and Posttransplant Outcomes in African Americans with Autoimmune Liver Diseases. <i>Journal of Transplantation</i> , 2021, 2021, 1-8.	0.5	5
12	The influence of equitable access policies and socioeconomic factors on post-liver transplant survival. <i>EClinicalMedicine</i> , 2021, 41, 101137.	7.1	7
13	Pregnancy in Chronic Liver Disease: Before and After Transplantation. <i>Annals of Hepatology</i> , 2021, 26, 100557.	1.5	2
14	Race/Ethnicity Is Not Independently Associated with Risk of Adverse Waitlist Removal among Patients with HCC Exception Points. <i>Journal of Clinical Medicine</i> , 2021, 10, 5826.	2.4	1
15	Bone Health in Patients With Liver Diseases. <i>Journal of Clinical Densitometry</i> , 2020, 23, 212-222.	1.2	27
16	The Pharmacologic Management of Osteoporosis in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Densitometry</i> , 2020, 23, 223-236.	1.2	8
17	Long-term outcomes after liver transplantation in the Hispanic population. <i>Liver International</i> , 2020, 40, 437-446.	3.9	20
18	Increased Posttransplant Mortality for Autoimmune Hepatitis Compared With Other Autoimmune Liver Diseases. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 648-654.	2.2	8

#	ARTICLE	IF	CITATIONS
19	Thinking Outside of Urso. <i>Clinical Liver Disease</i> , 2020, 16, 38-42.	2.1	0
20	New OPTN Simultaneous Liver-Kidney Transplant (SLKT) Policy Improves Racial and Ethnic Disparities. <i>Journal of Clinical Medicine</i> , 2020, 9, 3901.	2.4	1
21	Treatment of Overlap Syndromes in Autoimmune Liver Disease: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1449.	2.4	31
22	Nutrition in Cholestatic Liver Disease. <i>Current Hepatology Reports</i> , 2020, 19, 1-6.	0.9	1
23	Mortality on the UNOS Waitlist for Patients with Autoimmune Liver Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 319.	2.4	5
24	<p>Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges</p>. <i>Clinical and Experimental Gastroenterology</i> , 2020, Volume 13, 17-24.	2.3	12
25	Current and Emerging Treatment Options for Primary Biliary Cholangitis. <i>Gastroenterology and Hepatology</i> , 2020, 16, 363-365.	0.1	0
26	Pharmacologic management of primary sclerosing cholangitis: whatâ€™s in the pipeline?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 723-729.	3.0	7
27	Lipoprotein metabolism in liver diseases. <i>Current Opinion in Lipidology</i> , 2019, 30, 30-36.	2.7	13
28	Validation of Risk Scoring Systems in Ursodeoxycholic Acidâ€™Treated Patients With Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 1101-1108.	0.4	34
29	Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy. <i>Frontline Gastroenterology</i> , 2019, 10, 401-408.	1.8	14
30	Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2338-2350.	2.3	28
31	A Multicenter Evaluation of Adherence to 4 Major Elements of the Baveno Guidelines and Outcomes for Patients With Acute Variceal Hemorrhage. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 172-177.	2.2	12
32	Hospitalâ€™level balloon tamponade use is associated with increased mortality for all patients presenting with acute variceal haemorrhage. <i>Liver International</i> , 2018, 38, 477-483.	3.9	5
33	Osteoporosis in primary biliary cholangitis. <i>World Journal of Gastroenterology</i> , 2018, 24, 3513-3520.	3.3	29
34	Primary biliary cholangitis: new treatments for an old disease. <i>Frontline Gastroenterology</i> , 2017, 8, 29-36.	1.8	8
35	Suboptimal Implementation of Evidence-based Therapy for Acute Variceal Hemorrhage: A Systematic Review of Observational Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1373-1381.e7.	4.4	10
36	Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review. <i>American Journal of Medicine</i> , 2017, 130, 744.e1-744.e7.	1.5	28

#	ARTICLE	IF	CITATIONS
37	Hemostasis, bleeding and thrombosis in liver disease. <i>Journal of Translational Science</i> , 2017, 3, .	0.2	42
38	The Changing Role of Sodium Management in Cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , 2016, 14, 274-284.	0.8	11
39	The Reply. <i>American Journal of Medicine</i> , 2016, 129, e263.	1.5	0
40	Role of Noninvasive Fibrosis Methods in Management of Chronic Hepatitis B Virus. <i>Current Hepatology Reports</i> , 2016, 15, 220-229.	0.9	1
41	Preventing and Treating Acute Kidney Injury Among Hospitalized Patients with Cirrhosis and Ascites: A Narrative Review. <i>American Journal of Medicine</i> , 2016, 129, 461-467.	1.5	12
42	Prevalence of Abnormal Liver Function Tests in Celiac Disease and the Effect of a Gluten-Free Diet in the US Population. <i>American Journal of Gastroenterology</i> , 2015, 110, 1216-1222.	0.4	55
43	The Incidence and Outcomes of Ischemic Hepatitis: A Systematic Review with Meta-analysis. <i>American Journal of Medicine</i> , 2015, 128, 1314-1321.	1.5	113
44	Contemporary Assessment of Hepatic Fibrosis. <i>Clinics in Liver Disease</i> , 2015, 19, 123-134.	2.1	25
45	Hagen-Poiseuille's law: The link between cirrhosis, liver stiffness, portal hypertension and hepatic decompensation. <i>World Journal of Hepatology</i> , 2015, 7, 28.	2.0	9
46	Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law. <i>Liver Cancer</i> , 2014, 3, 428-438.	7.7	5
47	Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient. <i>Pharmaceuticals</i> , 2014, 7, 18-28.	3.8	1
48	Utilization of FibroScan in Clinical Practice. <i>Current Gastroenterology Reports</i> , 2014, 16, 372.	2.5	101
49	Current Therapies for Hepatorenal Syndrome. <i>Current Hepatitis Reports</i> , 2014, 13, 74-80.	0.3	2
50	Letter in Response to the Recently Published Review: Hyponatremia in Cirrhosis and End-Stage Liver Disease's Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan. <i>Digestive Diseases and Sciences</i> , 2013, 58, 889-890.	2.3	0
51	Biopsy No More; Changing the Screening and Diagnostic Algorithm for Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 309-310.	4.4	11
52	Evaluation of Liver Lesions. <i>Clinics in Liver Disease</i> , 2012, 16, 271-283.	2.1	48
53	Prevalence of Primary Biliary Cirrhosis's Autoimmune Hepatitis Overlap Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 609-612.	4.4	52
54	Methotrexate in Patients with Primary Biliary Cirrhosis Who Respond Incompletely to Treatment With Ursodeoxycholic Acid. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3207-3217.	2.3	27

#	ARTICLE	IF	CITATIONS
55	Effective use of FibroTest to generate decision trees in hepatitis C. World Journal of Gastroenterology, 2009, 15, 2617.	3.3	3